Stalevo/Comtan (Parkinson’s Disease) - Forecast and Market Analysis to 2022

GlobalData
March 31, 2014
62 Pages - GLDATA18026
$3,495.00

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Comtan (entacapone) was developed by Orion for Parkinson’s disease patients who experience end-of-dose wearing-off. The product, known as Comtan, is co-marketed with Novartis across the US, certain European markets, Brazil, and Japan. Orion has exclusive rights to the Nordic and Baltic countries, where the company is based, the UK, Ireland, and Germany, and is known as Comtess in these markets. Comtan/Comtess was first approved and launched in Europe in 1998, and launched a year later in the US. Additionally, entacapone is one of the active ingredients in Stalevo, a triple-combination pill with carbidopa, levodopa, and entacapone, co-marketed with Novartis.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Stalevo including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Stalevo for the top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Stalevo performance
- Obtain sales forecast for Stalevo from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Brazil).

'

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis - The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson’s Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson’s Disease Assessment Scales 29
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Product Profiles - COMT Inhibitors 37
6 Stalevo/Comtan (entacapone) 38
6.1 Overview 38
6.2 Efficacy 41
6.3 Safety 42
6.4 SWOT Analysis 43
6.5 Forecast 43
7 Appendix 45
7.1 Bibliography 45
7.2 Abbreviations 49
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Parkinson’s Disease Patients 52
7.4.2 Percent Drug-Treated Patients 53
7.4.3 General Pricing Assumptions 53
7.4.4 Compliance Assumptions 54
7.4.5 Individual Drug Assumptions 55
7.4.6 Generic Erosion 56
7.5 Physicians and Specialists Included in this Study 57
7.6 About the Authors 59
7.6.1 Author 59
7.6.2 Global Head of Healthcare 60
7.7 About GlobalData 61
7.8 Disclaimer 61

1.1 List of Tables
Table 1: Symptoms of Parkinson’s Disease 19
Table 2: UK Brain Bank Diagnostic Criteria 21
Table 3: Diagnosis and Treatment Guidelines for Parkinson’s Disease 22
Table 4: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014 23
Table 5: Dopaminergic Therapy in Parkinson’s Disease 26
Table 6: UPDRS Clinical Assessment of Disease Severity 31
Table 7: Parkinson’s Disease Assessment Scales Used in Clinical Trials 33
Table 8: Treatment of Motor Symptoms in Parkinson’s Disease 35
Table 9: Leading Treatments for Parkinson’s Disease, 2014 36
Table 10: Product Profile - Stalevo 40
Table 11: Product Profile - Comtan 41
Table 12: Stalevo/Comtan SWOT Analysis, 2014 43
Table 13: Global Sales Forecasts ($m) for Stalevo/Comtan, 2012-2022 44

1.2 List of Figures
Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 25
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson’s Disease 27

$3,495.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax